Thoracent

Minimally invasive devices for managing pleural effusions, restoring airway patency, and improving quality of life, along with an expanded suite of GI tools.

Learn more about Thoracent

Diagnostics

Developing molecular diagnostics to triage patients and ensure they get fast and effective care when they need it.

Learn more about Diagnostics

Biopsy Tools

Developing a suite of steerable endobronchial instruments to target difficult-to-reach off-airway nodules.

Learn more about our Biopsy Tools

Leadership

Maverix leadership combines decades of clinical, technical, and operating experience.

Learn more about our leadership

Advisors

The Maverix Medical Advisory Board is comprised of leading pulmonary physicians.

Meet our advisors

Partners

Maverix collaborates with firms that are transforming medtech innovation.

See our partners
Most Recent Article
Fierce Biotech
March 29, 2024

Lung Cancer Startup Maverix Medical Snaps Up Diagnostic Developer Cirrus Bio

Read More
PR Newswire
March 29, 2024
Maverix Medical Closes Acquisition of Cirrus Bio as Foundation for Diagnostics Platform in Lung Cancer
Read More
Wall Street Journal
November 30, 2023
Startup Ajax Health Extends Medtech Innovation Model to Hologic
Read More

Maverix Diagnostics

Sales Inquiries
Customer Care

About

We are developing a diagnostic test that aims to better clarify for physicians which patients are most likely to benefit from either tissue sampling or continued monitoring. This helps focus efforts on patients who require more active intervention to improve their outcomes.

Unique Benefits

Early detection and resection is crucial…
More than half of stage I patients are cured by a single surgery.
Unfortunately, 1/4 of CT scans identify a lung nodule, but few are cancer, creating diagnostic uncertainty.
because time is the enemy…
Patients often wait months to see a pulmonologist.
We currently diagnose over time, so doctors must wait to see if a nodule grows on CT scans.
...and a diagnostic will change everything.
Diagnostics identify high-risk patients and moves them to the front of the line for a biopsy.
Their cancer is quickly diagnosed and resected and is less likely to recur.